From cloudy to clear: visualising complex data privacy information
April 17, 2026 | clinical trials, communication, health literacy
Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.
For the final instalment of our Health Literacy series, we’re sharing another example of how we apply clear communication principles in practice. Here, we explore how we approached a crucial topic in clinical research: participant data.
Medical data is private – it’s sensitive and not something you want to share with strangers. The lack of transparency around how clinical trial data is stored and used can be a major barrier to participation, particularly for underrepresented communities.
We understand the complexity that comes with this topic. There are so many regulations, nuances, and technicalities to consider, which often means the information reads like a Terms & Conditions page. Although the reader has been “informed”, have they really read it? And more importantly, do they really understand?
Our “before” and “after” example shows how a simple flow diagram can help to translate this critical information so anyone can understand how their personal data may be shared.
Before:
The language is contractual and uses technical terms withoutcontext. It’s difficult to know what data your doctor, a researcher, or thebroader scientific community might be able to see.
After:
We’ve broken this information down into a flow diagram, clearly calling out the steps in place to ensure personal data are not identifiable. We made use of visual cues to emphasise that the data becomes more difficult to identify when it is processed and shared. Finally, using real examples of the types of data that may be collected helps provide the transparency readers are looking for.
Ultimately, we’ve provided a clear, visual commitment, supported with examples, to illustrate exactly how readers can expect their personal data to be used.
Clear communication about participant data isn’t just a regulatory requirement – it’s essential for building trust in clinical research. By presenting complex information in ways that people can easily understand, we can help more participants make informed decisions about taking part in clinical trials.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Clarity in clinical trials
Discover how transparent, empathetic communication and health literacy principles can empower patients and enhance engagement in clinical trials, transforming participants into active partners in their healthcare journey.
Caring for patients’ mental health in clinical trials
We look at why ensuring continuous mental health support for patients in clinical trials is essential to enhance their overall well-being and trial engagement.
Driving equitable healthcare: The role of DE&I in clinical trials
Diversity, equity and inclusion (DE&I) is becoming a bigger topic of conversation and meaningful action within clinical trials. And for good reason, too. Find out why we embrace this and…
Empowering patients through more accessible clinical trial information
Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial…
New report now available: Integrating ‘patient first’ into medicine development
A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map…
The digital prescription – enhancing the patient experience with technology
We explore how digital health innovations are revolutionising patient care by enhancing accessibility, personalisation, and engagement, promising a more connected and empowered patient experience.
Compliance — a driving force for influencing public perceptions of the pharma industry?
How does compliance play into public perceptions of pharma and why is it important for improving public opinion?
Another year, another B!
Louise Jones, Cuttsy+Cuttsy’s Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.
Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director
Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.
Clinical trial considerations: Why supporting HCPs matters…
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.